Document 2717
 DOCN  M94A2717
 TI    Cross-reactivity of particle agglutination test for antibody to HIV-2.
 DT    9412
 AU    Handa N; Maeda Y; Kato M; Tokyo Metropolitan Komagome Hospital, Japan.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):240 (abstract no. PB0390). Unique
       Identifier : AIDSLINE ICA10/94369858
 AB    OBJECTIVE: We purposed to examine the prevalence of HIV-2 infection in
       the persons with HIV-1 infection in our hospital and to test
       cross-reactivity of particle agglutination (PA) test for antibody to
       HIV-2. METHODS: PA test for antibody to HIV-2 was performed on 253 serum
       samples from persons with HIV-1 infection. These samples had been
       determined reactive by HIV-1 PA test and HIV-1 Western blot. The anti
       HIV antibody titer was expressed as the reciprocal of the highest
       dilution of serum giving a positive reaction. Serum samples repeatedly
       reactive by PA test were tested by Lav blot 1,2 and Pepti-lav 1,2. The
       profiles were interpreted by WHO criteria. RESULTS: Of the 253 samples
       tested, 196 were reactive at 1:32 only by HIV-1 PA test, 57 were
       reactive by both HIV-1 and HIV-2 PA test at 1:32 and 1:64 respectively.
       The highest titer of anti HIV-1 antibody was 10,000,000, and that of
       anti HIV-2 antibody was 64,000. The titer ratios (HIV-1/HIV-2) ranged
       from 10 to 39,063. Of the 57 specimens with positive HIV-1 and HIV-2 PA
       results, none was reactive by HIV-2 Western blot. DISCUSSION AND
       CONCLUSIONS: A total of 253 persons were confirmed as HIV-1 infected. No
       person with HIV-2 infection or double infection was detected.
       Cross-reactivity ratio was 22.5% (57/253).
 DE    *Agglutination Tests  *AIDS Serodiagnosis  Blotting, Western  Cross
       Reactions/*IMMUNOLOGY  Human  HIV Antibodies/*BLOOD  HIV
       Seropositivity/*DIAGNOSIS/IMMUNOLOGY  HIV Seroprevalence
       HIV-1/*IMMUNOLOGY  HIV-2/*IMMUNOLOGY  Predictive Value of Tests  MEETING
       ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).